Author: admin

How the Founders of 7Yards Media Achieved a $100 Million Industry Milestone for Small and Medium E-commerce Business

According to founders Lakshita Kapoor and Sahib Singh, this achievement underscores the company’s commitment to empowering SMBs across Australia through strategic e-commerce solutions that drive growth and enhance profitability.

7 Yards Media, a leading Australian e-commerce company, has announced an industry milestone, generating $100 million for small to medium-sized businesses (SMBs).

In a roundtable discussion with members of the Australian press this week, Lakshita Kapoor and Sahib Singh, founders of 7 Yards Media, attribute this milestone to the team’s dedication to helping clients achieve substantial financial outcomes.

“At 7 Yards Media, we believe that small to medium-sized businesses are the true drivers of innovation and community growth,” Sahib said. “Our focus has always been on creating strategies that enable these businesses to scale effectively and achieve their revenue goals.”

Sahib Singh, 7Yards Media Founder and Director

Sahib talked about an Australian jewellery brand that struggled with stagnant sales and ineffective marketing strategies and faced significant challenges in growing its revenue. After partnering with 7 Yards Media in February, the company received a tailored strategy that focused on targeted optimisation and scaling initiatives. As a result, the brand experienced a 145% increase in revenue within 90 days. Its monthly revenue surpassed $75,000, and it experienced a 79% increase in the number of orders.

“Our strategic scaling business efforts have been pivotal in transforming the business,” noted Sahib, who highlighted the company’s role in turning an underperforming business into a thriving e-commerce.

7Yards Media called on Australian SMBs to embrace innovative strategies and expert interventions to transform their e-commerce businesses. They urged small to medium-sized enterprises to seek support to address their specific challenges rather than settling for generic solutions that favour larger industry players.

“Our mission is to give these businesses the tools and visibility they need to not just survive but thrive in a competitive marketplace,” Lakshita noted.

Lakshita Kapoor, 7Yards Media Co-founder and Creative Director

A furniture reseller who struggled with poor sales and slim profit margins also turned to 7Yards Media for support. Generating only $24,000 per month in revenue and grappling with a conversion rate of just 0.3%, this client had inefficient ad campaigns and a low conversion rate, putting the business on the brink of closure.

In this case, 7Yards Media implemented targeted digital marketing strategies, including refined ad campaigns, enhanced audience targeting, and conversion rate optimisation. The company’s monthly revenue surged to $66,500, achieving a 107% increase in revenue, a 48% increase in conversion rate, and a 62% increase in gross profit.

Lakshita said 7 Yards Media’s approach is centred on a holistic e-commerce strategy that addresses both the front-end user experience and backend operational efficiency.

The team behind Yards Media executes data-driven methods to optimise ad performance and user experience. This leads to higher conversion rates and improved overall campaign effectiveness. The company’s commitment to data and analytics allows it to fine-tune strategies and ensure clients achieve their goals.

7 Yards Media also employs a comprehensive full-funnel approach, which aims to address every stage of the customer journey, from awareness to conversion. “This strategy aims to drive conversions at all touchpoints, making the most of every interaction a potential customer has with a brand,” explains Sahib.

Meanwhile, Lakshita pointed out that the challenges many e-commerce brands face, such as stagnant sales, marketing confusion, uncertain ROI, and limited time and resources, can be effectively managed through a strategic partnership with the right agency.

“At the end of the day, the goal is not to add more complexity. It is about offering a complete marketing solution that simplifies the growth path,” said Lakshita, who described the company’s combination of data-driven strategies, creative insight, and relentless focus on results as a game-changing approach in the Australian e-commerce landscape.

Through its approach, 7 Yards Media aims to help businesses stop playing catch-up and build winning marketing strategies that drive consistent, predictable growth.

For more information about 7 Yards Media and its services, visit https://7yardsmedia.com.au/.

About 7 Yards Media:

7 Yards Media is an Australian e-commerce company that aims to help small to medium-sized businesses achieve growth through strategic, data-driven marketing solutions. 7 Yards Media, led by founders Lakshita Kapoor and Sahib Singh, focuses on providing SMBs with the tools and strategies needed to thrive in a competitive marketplace, driving substantial results through innovative e-commerce solutions.

Media Contact
Company Name: 7 Yards Media
Contact Person: Sahib Singh
Email: Send Email
Phone: +61 470296306
Country: Australia
Website: https://7yardsmedia.com.au/

Beyond Translation: Discover How Timekettle’s W4 Pro AI Interpreter Earbuds Are Shaping the Future of Multilingual Interaction

The W4 Pro AI Interpreter Earbuds, presented at the International Funkausstellung (IFA) 2024, is Timekettle’s latest innovation and a global leader in AI-powered translation devices. Timekettle is happy to announce this news. These ground-breaking earbuds transform how we communicate in multilingual environments, catering to the increasing need for seamless cross-language communication. With the W4 Pro, you can go abroad, entertain foreign visitors, and participate in multilingual meetings with a smooth, hands-free experience far beyond standard translation techniques.

A Step Up From Conventional Translation Approaches

Globalization fosters contact between people speaking different languages and cultures, yet the translation systems now in use frequently cannot provide utterly fluid communication. To meet this problem, Timekettle created the W4 Pro, which provides an experience beyond simple translation. Timekettle CEO Leal Tian says, “Interpreter earbuds like the W4 Pro are essential even when phones can be used for translation because they cater to a more refined and immersive user experience.”

The W4 Pro makes hands-free, real-time communication that seems intuitive and natural possible, unlike phone-based translation programs that break up the natural flow of speech. Its elegant appearance, cutting-edge AI features, and excellent translation accuracy make it the perfect travel or business partner for anybody wishing to cross linguistic borders easily.

Three Modes for Diverse Communication Needs

The three unique communication modes that Timekettle’s W4 Pro offers are specifically designed to handle particular multilingual scenarios. The one-on-one simultaneous interpreting mode is ideal for private conversations since it allows for seamless, real-time translation in both directions. The dual interpretation technology of the W4 Pro guarantees uninterrupted conversation flow by allowing both speakers to speak and listen simultaneously. Incorporating a triple microphone array further improves accurate translation and voice recognition.

The Listen & Play option provides a perfect answer for people managing multilingual meetings. With real-time translations facilitating a seamless information flow, this mode lets users quickly move between speaking and listening. The AI Semantic Segmentation engine on the W4 Pro guarantees quick sentence parsing, and the AI Memo feature generates insightful post-meeting summaries so users can concentrate on the conversation rather than worrying about taking notes.

The third mode is for internet communication, including video conferences, foreign content streaming, and impromptu multilingual phone conversations. The W4 Pro ensures that every word is understood clearly by providing post-event audio analysis and real-time translated subtitles. Furthermore, users may easily understand crucial information during phone conversations with one-way assisted translation, which improves the effectiveness and accessibility of cross-language communication.

Comfort Meets High-End Sound Quality

Timekettle’s W4 Pro boasts state-of-the-art technology but is also ergonomically designed. The earbuds’ open-ear design guarantees comfort that lasts for a long time, even with prolonged use. The W4 Pro has a clean, comfortable fit that differentiates it from conventional in-ear headphones, making it ideal for lengthy meetings or travel.

The W4 Pro has an ergonomic design and produces excellent sound quality on par with audio systems used in professional settings. This premium sound performance ensures that every business or social discussion is crystal clear, enabling a more profound and engaging communication experience.

A Milestone Toward Universal Communication

The idea of the “Babel Fish,” a made-up character from The Hitchhiker’s Guide to the Galaxy that speaks any language, has long inspired Timekettle. Timekettle has made tremendous progress in realizing this goal throughout the years. Timekettle has continuously pushed the limits of cross-language communication, starting with its early invention of handheld translators and continuing with the ground-breaking creation of simultaneous interpreting earbuds.

The most recent and sophisticated version of this voyage is the W4 Pro. Enabling two-way, real-time communication that feels as natural as speaking the same language, Timekettle’s unique HybridCommTM technology is incorporated into the W4 Pro, building on the popularity of its predecessors, which included the WT2 Plus and M3 Translator Earbuds. When Timekettle improved its technology earlier this year, it could simultaneously interpret audio from many participants in five different languages, raising the bar for cross-language communication.

Timekettle is getting closer to realizing its ultimate dream of unrestricted communication freedom with the W4 Pro. In an increasingly globalized society, this ground-breaking solution breaks down barriers and promotes greater understanding by enabling users to engage effortlessly across cultural and linguistic boundaries.

About Timekettle

Established in 2016, Timekettle has become a prominent player in the world of artificial intelligence-powered translation systems. The company has been acknowledged for its cutting-edge products with multiple international awards, such as the CES Innovation Award, Japan Good Design Award, and iF Design Award. More than 400,000 industries, including business, education, tourism, and logistics, rely on Timekettle’s products worldwide.

With the same simplicity and fluency as communicating in one language, Timekettle is committed to making bidirectional conversation possible. The business is getting closer to a time when language barriers with eacwon’t products won’t hamper genuine human interaction by pushing the limits of AI translation technology.

For additional details regarding the business and its offerings, go to https://www.timekettle.co.

Media Contact
Company Name: Timekettle
Contact Person: Jocelyn Jiao
Email: Send Email
City: Shenzhen
Country: China
Website: https://www.timekettle.co/

How DRP Accelerator® Reduces Wastewater Treatment Costs by Cutting Solids Disposal by 50%

How DRP Accelerator® Reduces Wastewater Treatment Costs by Cutting Solids Disposal by 50%

“With DRP Accelerator®, facilities can reduce their solids disposal by up to 50%, resulting in significant cost savings over time.”
Innovative Bio-Accelerator Technology Lowers Operating Expenses for Wastewater Treatment Plants and Lagoons

Sep 16, 2024 – Houston, TX – DRP Chemicals, a leader in sustainable wastewater treatment solutions, introduces DRP Accelerator®, a cutting-edge bio-accelerator product designed to help wastewater treatment plants, lagoons, and industrial facilities significantly reduce solids disposal and operating costs. By accelerating the reproduction of bacteria that breakdown organic solids within wastewater systems, DRP Accelerator® delivers cost savings while improving system efficiency and reducing environmental impact.

“Wastewater facilities face the constant challenge of managing high volumes of organic solids, which increases the cost of disposal and strains their operational budgets,” said Matthew Dude of DRP Chemicals. “With DRP Accelerator®, facilities can reduce their solids disposal by up to 50%, resulting in significant cost savings over time.”

A Powerful Solution for Solids Management

The accumulation of solids in wastewater systems presents a significant challenge for operators. Solids disposal, including the costs associated with hauling, treating, and landfilling, can account for a major portion of wastewater facility operating expenses – often one of the top 3 highest costs. Traditional treatments may slow down the buildup of solids, but they don’t provide long-term, cost-effective solutions.

DRP Accelerator® changes the game by using a bio-accelerator technology that increases the growth and reproduction of natural bacteria already present in the wastewater system. This allows the bacteria to consume organic solids more rapidly and efficiently, resulting in a dramatic reduction in the volume of solids that must be disposed of.

By cutting the need for frequent solids removal, DRP Accelerator® helps facilities:

  • Reduce solids disposal by up to 50%: DRP Accelerator® accelerates the breakdown of organic solids, resulting in a significant reduction in waste volume that needs to be processed or removed from the system.
  • Lower operational costs: Fewer solids mean fewer disposal costs, including the savings associated with transporting and treating sludge.
  • Increase system capacity: With less solid waste clogging the system, wastewater treatment plants and lagoons can process more water without the need for costly infrastructure upgrades.


Key Benefits of DRP Accelerator®

In addition to reducing solids, DRP Accelerator® offers wastewater treatment facilities and lagoons a range of other critical benefits:

  • Reduced wear and tear on equipment: By thinning out sludge and eliminating organic solids, DRP Accelerator® helps extend the life of key infrastructure, including pumps, pipes, and valves. This reduces the need for costly repairs and replacements over time.
  • Improved system efficiency: DRP Accelerator® improves throughput and capacity by allowing wastewater systems to process more volume with fewer disruptions due to solids buildup.
  • Environmental sustainability: The ability to reduce the volume of waste being disposed of helps facilities minimize their environmental footprint while improving the quality of the water they discharge.
  • Cost-effective solution: DRP Accelerator® offers an affordable, easy-to-apply solution that generates measurable cost savings for wastewater facilities without requiring expensive new equipment or infrastructure.


Simple, Safe, and Environmentally Friendly

DRP Accelerator® is completely non-toxic, non-flammable, and safe to use in all wastewater treatment systems, including municipal wastewater facilities, industrial lagoons, and agricultural waste systems. The product is easy to apply, requiring no special equipment or systems, and it can be used with both aerobic and anaerobic treatment processes.

The product’s environmentally friendly formulation makes it a smart choice for facilities committed to sustainability and regulatory compliance. With the ability to reduce solids without harmful chemicals or emissions, DRP Accelerator® aligns with environmental standards while delivering superior results.

About DRP Chemicals

DRP Chemicals is a leading innovator in wastewater treatment solutions, offering advanced bio-accelerator technology designed to improve the efficiency, safety, and environmental sustainability of wastewater systems. The company’s flagship product, DRP Accelerator®, is used in a wide range of applications, from municipal wastewater treatment plants to industrial and agricultural lagoons, helping clients reduce costs, increase system capacity, and achieve compliance with environmental regulations.

To learn more about DRP Accelerator® or to request a consultation, visit DRPChemicals.com or call (832) 808-1578.

Media Contact
Company Name: DRP Chemicals
Contact Person: Chris Denny
Email: Send Email
Phone: 832-808-1578
Address:27122 FM 2920
City: Hockley
State: TX
Country: United States
Website: https://drpchemicals.com

GobizKOREA Launches the ‘2024 GobizWEEK Promotion’ for International Buyers

Discounts of up to 50% and other promotions from August 28 to September 28

Seoul, Korea – GobizKOREA, an online B2B marketplace operated by the Korea SMEs and Startups Agency (KOSME), will host the ‘2024 GobizWEEK’ promotion for international buyers from August 28 to September 28.

GobizWEEK is an annual promotion that allows international buyers to purchase high-quality products from Korean SMEs and startups at discounted prices.

This year’s GobizWEEK includes a wide range of products across all categories on GobizKOREA, including both consumer goods and industrial goods. To facilitate successful export transactions, the promotion offers significant discounts and various social media events.

During the promotion period, international buyers who submit inquiries for products they are interested in can proceed with transactions at discounts of up to 50%. Additionally, buyers who send multiple valid inquiries will be entered into a draw to win additional prizes, such as Amazon gift cards.

A representative from GobizKOREA stated, “We hope that through this promotion, we can widely promote the excellence of Korean SMEs and startups to the global market, encouraging more international buyers to trust GobizKOREA’s products and expand their transactions.”

For more detailed information on the GobizWEEK promotion, please visit the link below:

https://www.gobizkorea.com/user/goods/gobizExhibitionView.do?speclKwanId=SPCCD0002581

Meanwhile, the Ministry of SMEs and Startups, along with the Korea SMEs and Startups Agency (KOSME), announced that the ‘Buy K-Festa 2023’ will be held during the same period, from August 28 to September 28. Alongside GobizWEEK, the ‘Buy K-Festa’ aims to promote sales of excellent SME and startup products, actively supporting Korean export companies in reaching global consumers.

About GOBIZKOREA

GobizKOREA offers reliable trade support services free of charge to facilitate the swift and easy export of high-quality products from Korean SMEs and startups to global markets.

In particular, through various themed online exhibitions, GobizKOREA provides tailored product information by category. If buyers have difficulty finding the right products or companies, GobizKOREA’s trade experts offer practical services by discovering suitable products and facilitating business matching, ensuring robust support for both exporters and importers.

Media Contact
Company Name: GobizKOREA
Contact Person: TAEWAN KIM
Email: Send Email
Country: South Korea
Website: www.gobizkorea.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: GobizKOREA Launches the \’2024 GobizWEEK Promotion\’ for International Buyers

Face Clinic Showcases Expertise at International Aesthetic Medicine Congress

Face Clinic Showcases Expertise at International Aesthetic Medicine Congress

Head of Face Clinic, Dr. Elena Shchelokova, said: “We express tremendous gratitude to Dr. Werner Lothar Mang, Dr. Jens Altmann (@dr.jensaltmann), and the entire team of Bodenseeklinik Lindau (@bodenseeklinik_mang) for the opportunity to participate in this important event.”
Face Clinic, a leading provider of aesthetic medicine, participated in the International IGÄM Society Congress in Lindau, Germany. Dr. Elena Shchelokova, Head Doctor at Face Clinic, presented innovative approaches to facial aging, reinforcing the clinic’s leadership in the field. The clinic offers advanced treatments such as contouring, botulinum therapy, mesotherapy, and thread lifts.

LINDAU, GERMANY – September 16, 2024 – Face Clinic, a leading provider of aesthetic medicine services, recently participated in the prestigious International IGÄM Society Congress, held on September 6-7, 2024, in Lindau, Germany. The event gathered top medical professionals from around the world to discuss and explore the latest advancements in aesthetic medicine.

During the congress, Dr. Elena Shchelokova, Head Doctor at Face Clinic, delivered a notable presentation titled “A New Look at Facial Aging: The Dental, Nasal, and Ophthalmic Faces.” Her report highlighted Face Clinic’s innovative methods and its unique approach to addressing facial aging from multiple perspectives. Dr. Shchelokova also introduced her concept of “Intellectual Cosmetology,” an approach she developed, which focuses on using a deep understanding of individual facial structures and personalized treatments to achieve natural and harmonious results.

“Our participation in this congress affirms Face Clinic’s leadership in the field of aesthetic medicine,” said Dr. Shchelokova. “We remain committed to offering our patients the most cutting-edge and effective treatments, including contouring procedures, botulinum therapy, mesotherapy, thread lifts, and our proprietary ‘Intellectual Cosmetology‘ approach, ensuring that our practices are aligned with the latest international trends and advancements.”

She further added, “We express tremendous gratitude to Dr. Werner Lothar Mang, Dr. Jens Altmann (@dr.jensaltmann), and the entire team of Bodenseeklinik Lindau (@bodenseeklinik_mang) for the opportunity to participate in this important event.”

The International IGÄM Congress provided a valuable platform for healthcare professionals to exchange knowledge and foster collaboration, paving the way for future developments in aesthetic medicine. Face Clinic’s participation underscores its dedication to remaining at the forefront of the industry.

About Face Clinic:

Face Clinic is a premier provider of aesthetic medicine services, offering state-of-the-art treatments and personalized care to help patients achieve their aesthetic aspirations. Led by Dr. Elena Shchelokova, the clinic prides itself on delivering excellence in aesthetic treatments, including Dr. Shchelokova’s “Intellectual Cosmetology” approach, and staying ahead of global trends to provide innovative solutions.

Media Contact
Company Name: Face Clinic
Contact Person: Schelokova Elena
Email: Send Email
Phone: +79266568808
Address:Prechistenka 13
City: Moscow
Country: Russian Federation
Website: faceclinicmoscow.com

Flowers by Impressions Brings Romance and Playful Gender Reveal to Life with Stunning Floral Designs at Summer Wedding

“Flowers by Impressions – Stunning Floral Designs at Summer Wedding”
Flowers by Impressions, located in Buford, GA and serving the metro Atlanta area, recently designed beautiful floral arrangements for a summer wedding in Metro Atlanta. Using pink, white, and blue hues, the florals reflected the couple’s romantic vision. A surprise gender reveal was incorporated into the design with playful pink and blue accents. The florist created elegant floral decor for the ceremony arch, bridal bouquets, reception centerpieces, and a striking fireplace display.

Buford, GA – Sep 16, 2024 – Flowers by Impressions, a premier wedding florist serving Atlanta metro area, known for its elegant and personalized floral designs, recently added a beautiful touch of romance and playfulness to a summer wedding at Vecoma at the Yellow River wedding venue. With soft blush pink, white, and blue blooms, the florals seamlessly tied together the couple’s romantic vision with a surprise gender reveal that left guests in awe.

A Perfect Blend of Romance and Fun

The wedding, held in June, featured an enchanting outdoor ceremony followed by a lavish reception. Flowers by Impressions took center stage in transforming the couple’s dream into reality, designing a floral-accented ceremony arch, elegant bridal bouquets, elevated centerpieces, and a stunning fireplace display. The florals were carefully selected to complement the couple’s chosen color palette of blush pink, white, and blue, creating a cohesive and sophisticated look throughout the day.

To read more about the beautiful summer wedding flowers used in this celebration, visit our full feature on this wedding on our website.

Floral Arch

bridal bouquet

wedding centerpiece

The highlight of the event was a surprise gender reveal, incorporated seamlessly into the floral arrangements. The design team at Flowers by Impressions used delicate pink and blue floral accents to amplify the joy of the moment, blending the playful reveal into the otherwise elegant atmosphere.

gender reveal

Tailored Floral Designs to Match Every MomentFrom the moment the couple reached out to Flowers by Impressions, it was clear that their wedding would require a creative and thoughtful approach. The couple envisioned a romantic outdoor ceremony framed by a floral arch, lush bridal bouquets, and centerpieces that elevated the reception to a luxurious level. Flowers by Impressions delivered just that, crafting personalized arrangements that reflected the couple’s style while enhancing the beauty of the venue.

The team carefully curated the florals to withstand the summer heat while ensuring they remained fresh and vibrant throughout the day. The tall centerpieces, featuring roses, hydrangeas, and greenery on gold stands, added height and elegance to the tables, while the cascading floral display on the fireplace created a dramatic focal point for the reception.

A Memorable Gender Reveal TwistOne of the most unique aspects of this wedding was the gender reveal, where Flowers by Impressions incorporated blue and pink floral accents to subtly signal the couple’s big announcement. The reveal was a delightful surprise for the guests, and the florals played a key role in making the moment even more special.

“Creating the perfect blend of elegance and playfulness was key to this event,” said Dina T, lead floral designer at Flowers by Impressions. “The florals weren’t just decorations; they helped tell the couple’s story, from their vows to the joyful gender reveal moment. We’re proud to have been part of such a meaningful and unforgettable day.”

About Flowers by Impressions

Flowers by Impressions is a leading wedding and event florist in the Buford area, known for crafting bespoke floral arrangements tailored to each client’s unique vision. With a reputation for creativity, attention to detail, and seamless execution, Flowers by Impressions brings love stories to life through breathtaking floral designs. From intimate gatherings to grand celebrations, their team works closely with couples to create one-of-a-kind events filled with beauty and elegance.

For more information or to inquire about wedding floral services, visit https://flowersbyimpressions.com/ or contact Dina T. at (404) 488-5038.

Contact:

Dina T.

Flowers by Impressions

(404) 488-5038 

https://flowersbyimpressions.com/

Media Contact
Company Name: Flowers By Impressions
Contact Person: Dina T
Email: Send Email
Phone: 404-488-5038
Address:4250 Ridge Rd
City: Buford
State: GA
Country: United States
Website: https://flowersbyimpressions.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Flowers by Impressions Brings Romance and Playful Gender Reveal to Life with Stunning Floral Designs at Summer Wedding

K1 Speed is Appointed As KartSim’s Official US Distributor And Is Launching The First Dedicated Kart Coaching Simulation Facility in the USA

KartSim, the leading manufacturer of the most realistic karting simulation hardware and software in the World, has signed an agreement with K1 Speed, making them their exclusive distributor in America. K1 Speed has been the world’s premier indoor go-kart racing operator since 2003, with 100 locations worldwide. As part of this agreement, K1 Speed’s premier outdoor racing site, K1 Circuit in California, is a 1.1-mile configurable circuit that will also house the country’s first dedicated Kart Coaching complex. This state-of-the-art facility will combine on-track coaching with the industry-leading virtual racing simulators from KartSim, offering drivers of all skill levels a complete platform for development.

Expressing their excitement at the announcement, Tony Irfan, the Managing Director and founder of KartSim, stated, “We are thrilled to partner with K1 Speed. We are excited to introduce our hardware and software solutions for kart drivers in the US Market. With the imminent launch of our KartSim Pro US Software we plan to bridge the gap between simulation and live racing and further help develop kart driver’s skills together with the Kart Coaching complex opening at K1 Circuit.”

“We will provide future racers with a top-notch facility where they can improve their skills on and off the track with our Kart Coaching complex,”  added David Danglard, CEO and founder of K1 Speed and K1 Circuit. ”We’re thrilled to lead this innovation and support drivers in elevating their skills to new heights. K1 Circuit’s Kart Coaching complex will be a unique facility that helps drivers achieve new performance levels and act as a showroom for Kart Drivers wanting to purchase the most advanced kart simulation.”

The new Kart Coaching complex at the K1 circuit will be America’s first facility that will combine the thrill of racing with an immersive atmosphere with KartSim’s pro simulators, designed to provide a turn-key simulation experience using the latest technologies. With their new partnership, the company hopes K1 will provide go-kart racing professionals an outlet to test their skills and take it to the next level.

For any questions, contact John Ratcliff at john@kart-sim.com

To learn more, please visit: 

https://www.kart-sim.com/

https://www.k1speed.com/

https://www.k1circuit.com/

Media Contact
Company Name: KartSim Ltd
Contact Person: John Ratcliff
Email: Send Email
Phone: +44 (0)1327 226 976
City: Silverstone
State: Northamptonshire
Country: United Kingdom
Website: www.kart-sim.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: K1 Speed is Appointed As KartSim’s Official US Distributor And Is Launching The First Dedicated Kart Coaching Simulation Facility in the USA

Interstitial Cystitis Clinical Trials 2024 (Updated): FDA Approvals, Medication, Pipeline, Therapies, Mechanism of Action, ROA and Companies by DelveInsight

“Interstitial Cystitis Clinical Trials”
Interstitial Cystitis companies are Seikagaku Corporation, UCB, Alivio Therapeutics, Merck, Teva Pharmaceutical, Integrative Therapeutics, Lipella Pharmaceuticals, Addex Therapeutics, Imbrium Therapeutics, Ironwood Pharmaceuticals, others.

(Albany, USA) DelveInsight’s, “Interstitial Cystitis Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Interstitial Cystitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.

For Interstitial Cystitis Emerging drugs, the Interstitial Cystitis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Acute Pyelonephritis pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

Request for Sample Pages:  Interstitial Cystitis Pipeline Analysis

 

Some of the key highlights from the Interstitial Cystitis Pipeline report:

  • The Interstitial Cystitis Pipeline report offers a rich analysis of 8+ key players and 10+ key therapies.
  • Interstitial Cystitis pipeline comprises therapies in different stages of the clinical phase such as include Certolizumab pegol, SI-722, IW-3300,  and many others expected to enter the Interstitial Cystitis market in the coming years.
  • Key companies strengthening the Interstitial Cystitis Pipeline are Merck & Co, Teva Pharmaceutical Industries, Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Addex Therapeutics, Seikagaku Corporation, UCB, Alivio Therapeutics, Imbrium Therapeutics, Ironwood Pharmaceuticals, and many others.
  • In July 2024, Ironwood Pharmaceuticals, Inc announced results of a Phase 2 Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate the Efficacy, Safety, and Tolerability of 2 Dose Levels of IW-3300 Administered Rectally for 12 Weeks to Treat Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
  • In June 2024, Imbrium Therapeutics announced results of a Multicenter, Randomized, Double-blind Placebo-controlled, Crossover Study to Investigate Effects of V117957 in Female Subjects With Interstitial Cystitis/Bladder Pain Syndrome
  • In May 2024, Vaneltix Pharma, Inc announced results of a Phase 2b, Open Label, Single-Arm, Multi-Center, Multiple Dose, 14-Day Study to Evaluate the Safety, Efficacy, and Frequency of Intravesical Administration of VNX001 in Acute Treatment of Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity

 

Some of the key Interstitial Cystitis companies working in the market are:

  • Merck & Co
  • Teva Pharmaceutical Industries
  • Integrative Therapeutics, Inc.
  • Lipella Pharmaceuticals, Inc.
  • Addex Therapeutics
  • Seikagaku Corporation
  • UCB
  • Alivio Therapeutics
  • Imbrium Therapeutics
  • Ironwood Pharmaceuticals, And Many Others.

 

Learn more about the emerging Interstitial Cystitis pipeline therapies @ Interstitial Cystitis Treatment Market

 

Interstitial cystitis Overview:

Interstitial cystitis (IC), also called bladder pain syndrome, is a chronic, or long-lasting, condition that causes painful urinary symptoms. Symptoms of IC may be different from person to person. For example, some people feel mild discomfort, pressure, or tenderness in the pelvic area. Other people may have intense pain in the bladder or struggle with urinary urgency, the sudden need to urinate, or frequency, the need to urinate more often. IC can occur at any age, including during childhood, but is most common in adult women and men. About twice as many women are affected as men.1 However, more men may struggle with IC than researchers originally thought. Some research suggests that women are more likely to develop IC if they have a history of being physically traumatized

 

Interstitial Cystitis Emerging Drugs

Certolizumab pegol: UCB

Certolizumab pegol (Cimzia) developed by UCB, Belgium is a recombinant, humanized F(ab)’ fragment of an antibody conjugated to polyethylene glycol to enhance its plasma half-life. It is in phase 3 stage of development for the treatment of Interstitial cystitis.

SI-722: Seikagaku Corporation

SI-722 is a novel chemical compound in which a steroid is conjugated with chondroitin sulfate using Seikagaku’s proprietary glycosaminoglycan modification technology and drug delivery systems (DDS). SI-722 injected into the bladder is thought to demonstrate long-lasting improvement in the conditions of frequent urination and bladder pain by releasing a steroid with an anti-inflammatory effect. SI-722 has completed a Phase I clinical study in the U.S. In November 2019, it is starting a Phase I/II clinical study. This clinical study will evaluate the drug for safety, tolerability, and pharamcokinetics, and will conduct an exploratory evaluation of its effectiveness.

 

Request a sample and discover the recent advances in Interstitial Cystitis treatment drugs @ Interstitial Cystitis Therapeutic Assessment

 

Interstitial Cystitis Analytical Perspective by DelveInsight

  • In-depth Interstitial Cystitis Commercial Assessment of products 

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

  • Interstitial Cystitis Clinical Assessment of products 

The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type, and MOA type across this indication.

 

Request a Interstitial Cystitis pipeline report sample @ Interstitial Cystitis Drugs and Therapies

 

Scope of the Interstitial Cystitis pipeline report

  • The Interstitial Cystitis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Interstitial Cystitis across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Interstitial Cystitis therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Interstitial Cystitis research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Interstitial Cystitis.

 

Dive deep into rich insights for new drugs for Interstitial Cystitis treatment, visit @ Interstitial Cystitis Clinical Trials and FDA Approvals

 

Table of Content:

Introduction

Executive Summary

Interstitial Cystitis: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Interstitial Cystitis Pipeline Therapeutics

  • Comparative Analysis

Interstitial Cystitis Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

  • Comparative Analysis

Certolizumab pegol: UCB

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Drug name: Company name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

Drug name: Company name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Interstitial Cystitis  Preclinical and Discovery Stage Products

  • Comparative Analysis

LYT 503: PureTech Health

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Interstitial Cystitis Products

  • Comparative Analysis

Interstitial Cystitis Companies

Interstitial Cystitis Key Products

Interstitial Cystitis Unmet Needs

Interstitial Cystitis Market Drivers and Barriers

Interstitial Cystitis Future Perspectives and Conclusion

Interstitial Cystitis Analyst Views

Interstitial Cystitis Companies

Appendix

 

About DelveInsight

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Interstitial Cystitis Clinical Trials 2024 (Updated): FDA Approvals, Medication, Pipeline, Therapies, Mechanism of Action, ROA and Companies by DelveInsight

Interstitial Lung Disease Clinical Trials 2024: FDA Approvals, Medication, Pipeline Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

“Interstitial Lung Disease Clinical Trials”
Interstitial Lung Disease companies are AstraZeneca, CSL Behring, Syndax Pharmaceuticals, Taiho Pharmaceutical, GenKyoTex, Kadmon Pharmaceuticals, Novartis, Ark Biosciences, Roche, PureTech Health, Avalyn Pharma, Bristol-Myers Squibb, Insmed, Bayer, HEC Pharm, Prometheus Biosciences, Boehringer Ingelheim, Genentech, FibroGen, Reata Pharmaceuticals, Regend Therapeutics, Beijing Continent Pharmaceutical, Avalyn Pharmaceuticals, aTyr Pharma, Bristol-Myers Squibb, and AdAlta, and others.

(Albany, United States) As per DelveInsight’s assessment, globally, Interstitial Lung Disease pipeline constitutes 120+ key companies continuously working towards developing 120+ Interstitial Lung Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Interstitial Lung Disease Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Interstitial Lung Disease Market.

The Interstitial Lung Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Request for Sample Report here @ Interstitial Lung Disease Pipeline Analysis 

 

Some of the key takeaways from the Interstitial Lung Disease Pipeline Report:

  • Interstitial Lung Disease Companies across the globe are diligently working toward developing novel Interstitial Lung Disease treatment therapies with a considerable amount of success over the years. 
  • Interstitial Lung Disease companies working in the treatment market are AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Cudetaxestat, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics,  Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical,Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, and others are developing therapies for the Interstitial Lung Disease treatment.
  • Emerging Interstitial Lung Disease therapies such as AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280,  Blade Therapeutics, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation,  Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others are expected to have a significant impact on the Interstitial Lung Disease market in the coming years.  
  • On March 2024, Boehringer Ingelheim announced a Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs).
  • On April 2024, Boehringer Ingelheim announced a Prospective, Observational Study on the Correlations Between Change in Lung Function and Change in Cough and Dyspnoea in Patients With Connective Tissue Disease-associated Progressive Fibrosing INTErstitial luNg diseaSE (CTD Associated PF-ILD) Treated With Nintedanib. The “INTENSE” Study.
  • On January 2024, aTyr Pharma, Inc. announced a Randomized, Double-blind, Placebo-controlled Proof-of-Concept (PoC) Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD).

 

Interstitial Lung Disease Overview

Interstitial lung disease (ILD) encompasses a diverse group of disorders characterized by inflammation and scarring of lung tissue, leading to impaired gas exchange. Common symptoms include progressive dyspnea (shortness of breath), cough, and fatigue. ILD can be caused by various factors, including environmental exposures (such as asbestos or silica dust), autoimmune diseases (like rheumatoid arthritis or scleroderma), medications, and genetic predispositions. Diagnosis often involves a combination of clinical evaluation, imaging studies (such as high-resolution CT scans), pulmonary function tests, and sometimes lung biopsies. Treatment aims to alleviate symptoms, slow disease progression, and improve quality of life, and may include medications like corticosteroids, immunosuppressants, or antifibrotic agents. In some cases, lung transplantation may be considered for advanced disease. Prognosis varies depending on the specific type and severity of ILD, with some forms having a better outlook than others. Early detection and management are crucial in optimizing outcomes for patients with ILD.

 

Get a Free Sample PDF Report to know more about Interstitial Lung Disease Pipeline Therapeutic Assessment- Interstitial Lung Disease Treatment Market

 

Interstitial Lung Disease Route of Administration

Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous

 

Interstitial Lung Disease Molecule Type

Interstitial Lung Disease Products have been categorized under various Molecule types, such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Interstitial Lung Disease Pipeline Therapeutics Assessment

  • Interstitial Lung Disease Assessment by Product Type
  • Interstitial Lung Disease By Stage and Product Type
  • Interstitial Lung Disease Assessment by Route of Administration
  • Interstitial Lung Disease By Stage and Route of Administration
  • Interstitial Lung Disease Assessment by Molecule Type
  • Interstitial Lung Disease by Stage and Molecule Type

 

DelveInsight’s Interstitial Lung Disease Report covers around 120+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Interstitial Lung Disease product details are provided in the report. Download the Interstitial Lung Disease pipeline report to learn more about the emerging Interstitial Lung Disease therapies- Interstitial Lung Disease Drugs and Therapies

 

Interstitial Lung Disease Pipeline Analysis:

The Interstitial Lung Disease pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Interstitial Lung Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Interstitial Lung Disease Treatment.
  • Interstitial Lung Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Interstitial Lung Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Interstitial Lung Disease market.

 

Download Sample PDF Report to know more about Interstitial Lung Disease drugs and therapies- Interstitial Lung Disease Therapeutics Market

  

Scope of Interstitial Lung Disease Pipeline Drug Insight    

  • Coverage: Global
  • Key Interstitial Lung Disease Companies: AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Cudetaxestat, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics,  Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical,Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, and others.
  • Key Interstitial Lung Disease Therapies: AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280,  Blade Therapeutics, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation,  Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others.
  • Interstitial Lung Disease Therapeutic Assessment: Interstitial Lung Disease current marketed and Interstitial Lung Disease emerging therapies
  • Interstitial Lung Disease Market Dynamics: Interstitial Lung Disease market drivers and Interstitial Lung Disease market barriers 

 

Request for Sample PDF Report for Interstitial Lung Disease Pipeline Assessment and clinical trials – Interstitial Lung Disease Clinical Trials and FDA Approvals

 

Table of Contents

1. Interstitial Lung Disease Report Introduction

2. Interstitial Lung Disease Executive Summary

3. Interstitial Lung Disease Overview      

4. Interstitial Lung Disease- Analytical Perspective In-depth Commercial Assessment

5. Interstitial Lung Disease Pipeline Therapeutics

6. Interstitial Lung Disease Late Stage Products (Phase II/III)

7. Interstitial Lung Disease Mid Stage Products (Phase II)

8. Interstitial Lung Disease Early Stage Products (Phase I)

9. Interstitial Lung Disease Preclinical Stage Products

10. Interstitial Lung Disease Therapeutics Assessment

11. Interstitial Lung Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Interstitial Lung Disease Companies

14. Interstitial Lung Disease Key Products

15. Interstitial Lung Disease Unmet Needs

16 . Interstitial Lung Disease Market Drivers and Barriers

17. Interstitial Lung Disease Future Perspectives and Conclusion

18. Interstitial Lung Disease Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Interstitial Lung Disease Clinical Trials 2024: FDA Approvals, Medication, Pipeline Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

Sedona Waterproofing Solutions Expands Crawl Space Waterproofing Services in Charlotte, NC

Sedona Waterproofing Solutions Expands Crawl Space Waterproofing Services in Charlotte, NC
Sedona Waterproofing Solutions, with over 20 years of experience, offers premier crawl space waterproofing, encapsulation, and foundation repair services across Charlotte, NC, and surrounding areas, ensuring homes are protected from water damage.

Concord, North Carolina – September 13, 2024 – Sedona Waterproofing Solutions, a leader in crawl space waterproofing Charlotte NC, proudly offers comprehensive waterproofing and foundation repair services to homeowners and businesses across the region. With a focus on preventing water damage, mold, and structural issues, Sedona Waterproofing Solutions provides reliable and effective services, including crawl space encapsulation Charlotte NC.

crawl-space-waterproofing-Charlotte-NC

As a locally owned and operated company with over 20 years of experience, Sedona Waterproofing Solutions understands the specific waterproofing needs of Charlotte, NC, and surrounding areas. Their team of certified specialists uses top-of-the-line materials and advanced technology to offer tailored waterproofing and repair solutions. From small leaks to more significant foundation concerns, Sedona Waterproofing Solutions delivers expert care, ensuring homes are dry, safe, and free from harmful mold and moisture buildup.

Homeowners seeking crawlspace encapsulation near me can rely on Sedona Waterproofing Solutions to provide a thorough assessment of their property. The company offers free inspections and quotes, providing clients with peace of mind knowing that their home or business is protected from the long-term effects of water damage. By encapsulating crawl spaces, Sedona Waterproofing Solutions effectively prevents moisture intrusion, mold growth, and structural degradation. This process not only enhances air quality but also prolongs the lifespan of the property.

“Committed to quality and customer satisfaction, Sedona Waterproofing Solutions stands behind its work with warranties on all services. With discounts available for military members and first responders, the company aims to make its services accessible to the entire community. The team of experts is also available 24/7 for emergency waterproofing needs, providing prompt assistance in times of crisis. Our dedication to high standards of service has earned us some of the best reviews in the industry.”

As the leading provider of Charlotte NC waterproofing, Sedona Waterproofing Solutions ensures that each project is completed with the utmost attention to detail. They offer low-cost annual maintenance programs to keep homes dry and protected throughout the year. Their services have been instrumental in safeguarding homes from the unpredictable effects of weather, soil conditions, and drainage issues.

About Sedona Waterproofing Solutions:

Founded in 2016, Sedona Waterproofing Solutions is a trusted waterproofing and foundation repair company serving Charlotte, NC, and surrounding areas. Specializing in crawl space waterproofing, foundation repair, and mold remediation, the company provides top-notch services backed by warranties and a commitment to customer satisfaction.

To learn more, visit https://www.sedonawaterproofing.com/.

Media Contact
Company Name: Sedona Waterproofing Solutions
Contact Person: Josh Landrio
Email: Send Email
Phone: +1 704-960-7906
Address:188 Crowell Dr NW
City: Concord, Cabarrus
State: North Carolina
Country: United States
Website: https://www.sedonawaterproofing.com/